PACB (Pacific Biosciences of California) Marketable Securities: $219.7 Mil (As of Mar. 2026)


PACB Pacific Biosciences of California Inc PACB
55 GF Score
Price $1.57
GF Value $1.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Marketable Securities?

Pacific Biosciences of California PACB -2.80% 55 Marketable Securities is $219.7 Mil as of Mar. 2026. GuruFocus rates PACB with a GF Score™ of 55/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pacific Biosciences of California's Marketable Securities for the quarter that ended in Mar. 2026 was $219.7 Mil.

Pacific Biosciences of California's annual Marketable Securities declined from Dec. 2023 ($451.5 Mil) to Dec. 2024 ($334.6 Mil) and declined from Dec. 2024 ($334.6 Mil) to Dec. 2025 ($215.8 Mil).

Pacific Biosciences of California  (NAS:PACB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Pacific Biosciences of California Marketable Securities Related Terms

Pacific Biosciences of California Marketable Securities Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California Marketable Securities Chart

Pacific Biosciences of California Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 583.68 447.23 451.51 334.56 215.80

Pacific Biosciences of California Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 284.60 259.93 242.19 215.80 219.69
PACB
55GF Score
Pacific Biosciences of California Inc PACB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Biosciences of California Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $219.7 Mil mean?
Pacific Biosciences of California (PACB) has a Marketable Securities of $219.7 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Marketable Securities too high?
Pacific Biosciences of California's current Marketable Securities is $219.7 Mil. Overall, Pacific Biosciences of California has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Marketable Securities compare to KIDS and MOBI?
Pacific Biosciences of California's Marketable Securities of $219.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Marketable Securities is $219.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.57 — trading 3.1% below its estimated fair value. The current Marketable Securities is $219.7 Mil. Pacific Biosciences of California's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Marketable Securities is $219.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.57 is trading 3.1% below its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

  • Marketable Securities: $219.7 Mil
  • GF Value™: $1.62 vs. price of $1.57 (3.1% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
55GF Score

Get the complete analysis for PACB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$1.62
GF Value